PT  - JOURNAL ARTICLE
AU  - Roohani, Borna
AU  - Mendez, Aldred Shane
AU  - Dangarwala, Mann
AU  - Katz, Samantha
AU  - Marquez-Nostra, Bernadette
TI  - Nuclear Imaging of Bispecific Antibodies on the Rise
AID  - 10.2967/jnumed.123.267215
DP  - 2024 Oct 01
TA  - Journal of Nuclear Medicine
PG  - 1512--1517
VI  - 65
IP  - 10
4099  - http://jnm.snmjournals.org/content/65/10/1512.short
4100  - http://jnm.snmjournals.org/content/65/10/1512.full
SO  - J Nucl Med2024 Oct 01; 65
AB  - Bispecific antibodies (bsAbs) are engineered to target 2 different epitopes simultaneously. About 75% of the 16 clinically approved bsAbs have entered the clinic internationally since 2022. Hence, research on biomedical imaging of various radiolabeled bsAb scaffolds may serve to improve patient selection for bsAb therapy. Here, we provide a comprehensive overview of recent advances in radiolabeled bsAbs for imaging via PET or SPECT. We compare direct targeting and pretargeting approaches in preclinical and clinical studies in oncologic research. Furthermore, we show preclinical applications of imaging bsAbs in neurodegenerative diseases. Finally, we offer perspectives on the future directions of imaging bsAbs based on their challenges and opportunities.